Literature DB >> 2096492

The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.

T Lindhout1, R Blezer, H C Hemker.   

Abstract

We studied the inhibitory action of recombinant desulphatohirudin (CGP 39393) on thrombin generation in whole plasma. Human plasma was activated either with thromboplastin or factor IXa. Hirudin delayed thrombin generation, but it was unable to prevent the explosive appearance of thrombin. The dose-dependent prolongation of the lag phase of the intrinsic and extrinsic thrombin generation curve was not the result of titration of thrombin activity by hirudin but the result of a delayed formation of the prothrombin converting complex (prothrombinase). In case of extrinsic activation, hirudin did not affect factor Xa generation, but prolonged the lag phase of the factor Va generation curve, causing its appearance when factor Xa generation was already in the decay phase. Because of its inhibitory action on the thrombin-mediated activation of factor VIII, hirudin prolonged the lag phase of the factor X converting complex that consists of factor IXa and factor VIIIa. Our observations with hirudin are in keeping with the notion that inhibition of the thrombin-mediated amplification reactions in blood coagulation is a very efficient way to delay or inhibit completely thrombin generation. However, although hirudin neutralizes stoichiometric amounts of thrombin, the interaction between in situ generated thrombin and hirudin appears not to be fast enough to prevent trace amounts of thrombin to activate factors VIII and V. Consequently, an explosive thrombin generation is observed even when free hirudin is present.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096492

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.

Authors:  Victor Serebruany; Yanti Sani; Donald Lynch; Alex Schevchuck; Stan Svetlov; Alan Fong; Lionel Thevathasan; Dan Hanley
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

Review 2.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

3.  Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

4.  Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.

Authors:  Michael Wolzt; Maria Wollbratt; Mia Svensson; Karin Wåhlander; Margaretha Grind; Ulf G Eriksson
Journal:  Eur J Clin Pharmacol       Date:  2003-09-04       Impact factor: 2.953

5.  Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.

Authors:  Sanne Bøjet Larsen; Erik Lerkevang Grove; Søs Neergaard-Petersen; Morten Würtz; Anne-Mette Hvas; Steen Dalby Kristensen
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.